Rx (Prescription Medicine)
USD $ 106.00
Pacliget 260mg 注射液是一种靶向疗法，用于治疗某些类型的癌症。其活性成分为帕克西太太（Paclitaxel），一种强效的化疗药物。帕克西太太通过干扰微管的正常功能发挥作用，微管是细胞分裂的关键组成部分。通过稳定微管，它阻止了癌细胞分裂和增殖所必需的分解过程，最终导致细胞死亡。Pacliget 260mg 注射液用于治疗晚期卵巢癌、晚期乳腺癌和非小细胞肺癌，通常与其他化疗药物联合使用。Paclitaxel的剂量和给药方式由合格的医疗专业人员根据具体的癌症类型、分期以及患者的整体健康状况来确定。常见的不良反应可能包括骨髓抑制（导致血细胞计数降低）、周围神经病变（神经损伤导致麻木或刺痛）、脱发、恶心、呕吐和过敏反应。出现任何不寻常或严重的不良反应时，请立即向医生报告。Paclitaxel 260mg 注射液应储存在室温并避光保存。其给药方式为静脉注射，需在严格的医疗监督下进行。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Paclitaxel. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
